Your browser doesn't support javascript.
loading
Rechallenge of voriconazole successfully tolerated after hepatic toxicity.
Narumoto, O; Suzuki, J; Takeda, K; Tamura, A; Nagai, H; Matsui, H.
Afiliação
  • Narumoto O; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
  • Suzuki J; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
  • Takeda K; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
  • Tamura A; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
  • Nagai H; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
  • Matsui H; Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, Japan.
Respir Med Case Rep ; 31: 101191, 2020.
Article em En | MEDLINE | ID: mdl-32904036
Infections caused by Aspergillus species are often life-threatening. Drugs effective for Aspergillus infection are limited. Voriconazole is one of the most important drugs, however, considerable portion of patients experience liver toxicity and have to stop the drug administration. We frequently experience liver toxicity even though the serum concentration of voriconazole is within the target range. Historically, in some life-threatening situations like tuberculosis, where a suitable alternative is unavailable, rechallenge has been attempted. However, there have been no report on the rechallenge of voriconazole. We report cases of successful re-administration of voriconazole after liver toxicity.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Idioma: En Revista: Respir Med Case Rep Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 3_ND Base de dados: MEDLINE Idioma: En Revista: Respir Med Case Rep Ano de publicação: 2020 Tipo de documento: Article